Zynerba sinks twice as cannabis trials flop; strike three looms, so where’s the Ouija board?
The News: Zynerba Pharmaceuticals Inc. (ZYNE) lost more than half its value last week to $7.03 after the drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage… Read more »